Mineralys Therapeutics, Inc./$MLYS
1D1W1MYTD1Y5YMAX
Capital at risk
About Mineralys Therapeutics, Inc.
Mineralys Therapeutics Inc is a biopharmaceutical company focused on developing medicines to target diseases driven by dysregulated aldosterone. The Company's product candidate, lorundrostat, is a proprietary, orally administered, aldosterone synthase inhibitor that the Company is developing for the treatment of cardiorenal conditions affected by dysregulated aldosterone, including hypertension and related comorbidities, such as chronic kidney disease and obstructive sleep apnea. Its product candidate, lorundrostat, is a proprietary, orally administered, selective ASI that is designed to reduce aldosterone levels by inhibiting CYP11B2, the enzyme responsible for producing the hormone.
- Ticker
- $MLYS
- Sector
- Health
- Primary listing
- NASDAQ
- Employees
- 76
- Headquarters
- Radnor, United States
- Website
- mineralystx.com
MLYS Metrics
BasicAdvanced
$2.8B
-
-$4.38
0.68
-
Price and volume
Market cap
$2.8B
Beta
0.68
52-week high
$47.65
52-week low
$22.30
Average daily volume
875K
Financial strength
Current ratio
34.464
Quick ratio
34.236
Long term debt to equity
17.719
Total debt to equity
17.719
Profitability
EBITDA (TTM)
-370.752
Management effectiveness
Return on assets (TTM)
-46.18%
Return on equity (TTM)
-80.88%
Valuation
Price to book
4.99
Price to tangible book (TTM)
4.99
Price to free cash flow (TTM)
-17.909
Free cash flow yield (TTM)
-5.58%
Free cash flow per share (TTM)
-1.738
Growth
Earnings per share change (TTM)
25.30%
3-year earnings per share growth (CAGR)
26.51%
Bulls say / Bears say
On March 9, 2026, the FDA accepted the NDA for lorundrostat, initiating a PDUFA review cycle targeting approval by December 22, 2026 (SEC).
Mineralys ended Q2 2026 with $661.4 million in cash, cash equivalents and investments, which management expects to fund operations, including the commercial launch of lorundrostat, into 2028 (GlobeNewswire).
Late-breaking proteomic data presented at ENDO 2026 demonstrated that lorundrostat produced significant reductions in heart failure risk biomarkers in over 1,000 patients, supporting potential label expansion into heart failure indications (GlobeNewswire).
Mineralys reported a Q2 net loss of $241.1 million, or $2.85 per share, compared to a $43.3 million loss, or $0.66 per share a year earlier, missing analyst expectations and reflecting high pre-launch costs (Reuters).
The company has not generated any revenue to date and remains entirely dependent on the unproven lorundrostat, exposing it to binary risk pending regulatory approval (SEC).
Under the amended license agreement with Mitsubishi Tanabe Pharma, Mineralys made a $200 million upfront payment and faces up to $255 million in additional milestone obligations plus $10 million for a second indication, increasing contingent liabilities ahead of revenue generation (GlobeNewswire).
Data summarised monthly by Lightyear AI. Last updated on 5 Sept 2026.
Upcoming events
No upcoming events
MLYS News
AllArticlesVideos
Funds containing MLYS
AllUSDGBPEUR
Fund name | Fund size | $MLYS weighting |
|---|---|---|
iShares Nasdaq US Biotechnology$BTEC | $1.2B | 0.16% |
iShares Nasdaq US Biotechnology£BTEK | £865M | 0.16% |
SPDR Russell 2000 US Small Cap€R2US | €4.8B | 0.06% |
iShares MSCI USA Small Cap ESG Enhanced CTB€SXRG | €2.8B | 0.02% |
iShares MSCI USA Small Cap CTB Enhanced ESG£CUS1 | £2.4B | 0.02% |
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.